Less than a week after starting the phase I trial with its lead NLRP3 antagonist, IFM-2427, Boston-based IFM Therapeutics LLC chalked up a contract potentially worth more than $1.5 billion for anti-inflammatory therapies with Novartis AG, which brings aboard the whole portfolio in the class via the buyout of subsidiary IFM Tre.